5407972026-04-012026-06-305407972026-06-305407972026-04-012026-06-30in-capmkt:OtherExpenses1Member5407972026-04-012026-06-30in-capmkt:OtherExpenses2Member5407972026-04-012026-06-30in-capmkt:OtherExpenses3Member5407972026-04-012026-06-30in-capmkt:OtherExpenses4Member5407972026-04-012026-06-30in-capmkt:ReportableSegments1Member5407972026-04-012026-06-30in-capmkt:ReportableSegments2Member5407972026-04-012026-06-30in-capmkt:ReportableSegments1Member5407972026-04-012026-06-30in-capmkt:ReportableSegments2Member5407972026-04-012026-06-30in-capmkt:ReportableSegments1Member5407972026-06-30in-capmkt:ReportableSegments1Member5407972026-04-012026-06-30in-capmkt:ReportableSegments2Member5407972026-06-30in-capmkt:ReportableSegments2Member5407972026-04-012026-06-30in-capmkt:ReportableSegments1Member5407972026-06-30in-capmkt:ReportableSegments1Member5407972026-04-012026-06-30in-capmkt:ReportableSegments2Member5407972026-06-30in-capmkt:ReportableSegments2Member5407972026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15407972026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540797SHALBYNOTLISTEDINE597J01018SHALBY LIMITEDMain BoardEquity2026-04-012027-03-312026-08-122026-07-27INRMillionsQuarterlyFirst quarterMulti segment2026-08-1217:13:002026-08-1218:15:00Not applicable2026-04-012026-06-30UnauditedConsolidated331224000074140000338638000082410000420100000134430000478580000105650000187440000178082000031894300001969500000196950000119470000-2748000091990000010496000000001049600004550000109510000108450000-3490000113000000-34900001075260000100.980.98000.980.98Notes to the Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026 <br /> <br /> 1. The above unaudited financial results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on August 12, 2026. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results. <br /> <br /> 2. These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter. <br /> <br /> 3. The figures for quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the financial year. <br /> <br /> 4. Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. Till June 30, 2026, Company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,42,765 Stock Options were lapsed and 2,16,235 options were vested and exercised by eligible employees. <br /> <br /> In accrodance with the resolution passed by Nomination and Remuneration Committee, the company has granted 1,33,000 stock options from the pool of 4,42,765 lapsed options. and as As of June 30, 2026, a total of 1,10,000 stock options remain active. <br /> <br /> 5. Shalby Medtech Limited (“SMTL”) (Wholly Owned Subsidiary Company of Holding Company), have implemented Employee Stock Option Scheme, namely Shalby Medtech Limited - Employees Stock Options Scheme – 2025, as approved by its shareholders. During quarter ended June 30, 2026, SMTL has granted 50,000 Stock Options convertible into equivalent number of equity shares of SMTL upon vesting, pursuant to said ESOP scheme. As on June 30, 2026, SMTL has granted total 11,41,000 Stock Options <br /> <br /> 6. Shalby Medtech Limited (“SMTL”), a Wholly-Owned Subsidiary of the Holding Company, at its meeting held today have aprpoved acquisition of balance 10,000 equity shares of Shalby Global Technologies Pte. Ltd. (“SGTPL”), Singapore, from two individual promoter shareholders. Consequently, SGTPL has become a wholly-owned subsidiary of SMTL with effect from August 12, 2026. <br /> <br /> 7. The consolidated financial result includes the results of the Company and 13 Subsidiary companies (Covering 3 stepdown subsidiaies). The company together with its subsidiaries is herein referred to as the "Group". <br /> <br /> 8. The Group is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated November 26, 2018. <br /> <br /> 9.As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Healthcare Activities & Manufacturing of Implant. Disclosure for the same is given in the separate note attached herewith in Annexure I. <br /> <br /> 10. Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.Materials and Consumables446150000Fees to Doctors and Consultants790560000Other Operative Expense223660000Other Expenses320450000Healthcare Services2888140000Manufacturing & Trading of Implants42410000033122400003312240000Healthcare Services311760000Manufacturing & Trading of Implants-114810000196950000196950000Healthcare Services12704340000Manufacturing & Trading of Implants583605000018540390000018540390000Healthcare Services4125320000Manufacturing & Trading of Implants4243930000836925000008369250000Items that will not be reclassified to profit or loss-580000-580000-150000Items that will be reclassified to profit or loss4980000498000004550000